Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

• Published in: Skin (Milwood, N.Y.) Vol. 7; no. 2; p. s116
• Main Authors: Lebwohl, Mark, Egeberg, Alexander, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Strober, Bruce
• Format: Journal Article
• Language: English
• Published: 13.03.2023

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the phase 3 POETYK PSO...